No Data
No Data
HK stock market shock | Kolonbotai Bioscience-B (06990) rose more than 4% in the morning, Merck has launched 10 global Phase III trials for SKB264.
Kolon Life Science - B (06990) rose more than 4% in the morning. As of press time, it has risen 2.32% to HKD 154.1, with a turnover of HKD 15.8229 million.
We Think Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) Can Easily Afford To Drive Business Growth
Kelon Botai Biotechnology-B (06990.HK) plans to hold a board of directors meeting on August 19th to approve its mid-term performance.
Kolon Life Science-B (06990.HK) announced on August 7th that the board of directors will hold a board meeting on August 19, 2024 (Monday) to consider and approve the mid-term performance of the company and its subsidiaries for the six-month period ended June 30, 2024, as well as to handle other matters.
SKB BIO-B: NOTICE OF BOARD MEETING
Hong Kong stock concept tracking | National Medical Products Administration approved the pilot program of optimizing the clinical trial review and approval of innovative drugs in Peking and Shanghai, and innovative drugs are expected to outperform other s
The pharmaceutical industry is expected to see overall year-on-year improvement and quarter-on-quarter growth in performance in the second half of the year.
China Post Securities: ADC drug innovation drives development, and the industry's high prosperity continues.
Several varieties with sales amounts reaching tens of billions of yuan are expected to emerge in the domestic ADC drug field, with many biopharmaceutical and biotechnology companies focused on layout. It is recommended to actively pay attention to pharmaceutical companies with smooth clinical progress and overseas prospects.
No Data